Trevi Therapeutics, Inc. Loans Payable, Current
Trevi Therapeutics, Inc. (TRVI) had Loans Payable, Current of $7.48 million as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Balance Sheet › Liabilities
us-gaap:LoansPayableCurrent · last filed 2024-03-20
- 2023-03-31: Loans Payable, Current $7.48M.
- 2022-12-31: Loans Payable, Current $7.00M.
- 2022-09-30: Loans Payable, Current $7.00M.
- 2022-06-30: Loans Payable, Current $7.00M.
| Period end | Loans Payable, Current |
|---|---|
| 2023-03-31 | $7.48M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $7.00M 10-K · filed 2024-03-20 |
| 2022-09-30 | $7.00M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $7.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $7.00M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $5.83M 10-K · filed 2023-03-16 |
| 2021-09-30 | $4.08M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $2.33M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $583.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |